Developing a Successful Biopharmaceutical
Pricing & Market Access Strategy

P&MA course, Thursday May 23rd – July 11th 2024 (1pm – 3 pm BST)

Registration is now open for “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy”, our executive education programme, which is a collaboration between
Windrose Consulting Group and the University of Cambridge faculty of Bioscience Enterprise.

Course Overview

A Pricing & Marketing Access (P&MA) course, to develop the knowledge and skills required to deliver a successful Life Science commercial strategy and become an industry leader.

This executive education programme is a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE).

The course is a blend of lectures, case studies and practical exercises. We believe in an interactive approach, encouraging group discussion and exploring real-world situations. The aim is not just to provide the theory, but help you understand how to apply it within your role or future career.

What Will You Learn?

You will gain an in-depth understanding of how to achieve commercialisation excellence:

  • Develop and implement a successful Pricing & Market Access strategy

  • Understand how to pre-empt and address commercialisation challenges

  • Effectively communicate the value of a drug

  • Create strategies to adapt to a rapidly changing Life Science landscape

  • Learn the theory and application of commercialisation strategy; with real life case studies, course work & feedback

Who Should Attend?

This course is aimed at present and future Life Science leaders.

Typical participants are:

  • Experienced professionals who wish to gain a strong understanding of commercialisation strategy

  • Those who are entering or transitioning into the commercial side of Life Sciences

  • Pricing & Market Access professionals seeking career advancement

  • Those interested in learning about, or a career in, the Life Sciences industry

Location & Dates

  • The virtual course will be run over 7 sessions, on Thursdays from the 23rd of May – 11th of July 2024 (1pm – 3 pm BST).

Enrollment fees

  • Full course £2,500 (Group discounts available, please contact us for more information)

What this includes?

  • Expert tuition

  • Course materials (digital copies) and course video recordings

  • Certificate of completion

What our course alumni are saying

“As I was transitioning from public affairs to market access, The Windrose course gave me a strong foundation to navigate the payer environment and enhance the value that market access brings to the overall pharma business strategy. I would recommend this course to any pharmaceutical executive interested in developing their market access skills and knowledge through a well-structured and hands-on approach”

— Marie Blanchard, Head of Patient Access Strategy, Myastenia Gravis portfolio, UCB

“Having recently completed Windrose's market access and pricing course, I can attest to its exceptional quality. The course stands out for its in-depth content, real-world applicability, and expert-led insights. The course not only broadened my understanding of industry dynamics but also provided actionable and practical strategies that have proven instrumental in my role. From the MA&P fundamentals to the integrated stakeholder analysis, navigating payer systems and archetypes, crafting a compelling value story, and mastering pricing and negotiation strategies. I wholeheartedly endorse this program to fellow professionals aspiring for a knowledge expansion and competitive edge in the ever changing pharmaceutical market access world.“

- Ahmed Eladawi, Head of Global Market Access and Pricing, Organon

“The Developing a Successful Biopharmaceutical Pricing & Market Access Strategy course was really helpful to understand what is needed to create a strong strategy and communicate the value of the product. The structure of the course allow you to interact with other colleagues and learn from their experiences when facing similar challenges. Even if you have been working in market access & pricing for a long time or you are new to the field, the examples provided during the course are useful and of great value for everyone.”

— Amilcar Azamar, Director, Global Value & Access, Gilead Sciences

"The course was well thought through and structured, not only in terms of lectures, interactive parts and materials, but also in terms of providing helpful approaches, workflows and tools for your everyday work environment. For me in a global strategic role the iterative integration of P&MA strategy into business development, product positioning and commercial strategy is of great value. Overall, it was a very insightful, hands-on and truly inspiring course that I definitely recommend!”

— Pascal Dammeyer, Chief Business Officer, HemostOD

Register your interest in the form below

Register and pay though the Cambridge University Website

Course Leaders

  • Matt Storer

    Matt is a managing partner at Windrose and head of European operations. He has been advising the industry for 17 years and has led the course for the past seven. Matt brings a breadth of experience across therapeutic domains and technologies, and enjoys teaching how to simplify complex problems.

  • Zameer Merchant

    Zameer is a Senior Principal with over 11 years of consulting experience in helping life science companies navigate the complexities of commercialising pharmaceutical and medical technologies.

  • Anais Frappe

    Anais is a Senior Principal at Windrose. She has over 13 years of working experience in the Life Sciences industry globally, spanning across market access & pricing, sales & commercial, private equity, medical affairs, regulatory, and organisational design.

  • Andrew Walker

    Andrew Walker

    With 14 years of experience at the Scottish Medicines Consortium (SMC), Dr. Walker helped establish the system for submission and review of economics evidence leading 144 industry submissions across therapy areas. Dr. Walker is also a Senior lecturer in Health Economics at Glasgow University.

  • Professor Seamus Higson

    Professor Seamus Higson is joint Programme Director for the M.Phil. in Bioscience Enterprise (MBE) within the Department of Chemical Engineering and Biotechnology of the University of Cambridge. His career to date has spanned academic departments of Chemistry, Medicine, Biotechnology, Materials Science and Engineering.

  • Dr David Hampton

    Dr David Hampton

    Dr David Hampton is Programme Director for Bioscience Enterprise at the University of Cambridge. His academic work, applying machine intelligence to clinical opportunities in remote patient management, has yielded over 30 granted patents.

  • Professor Lisa Hall

    Professor Lisa Hall is an experienced leader and innovator in Academia, Technology Start-ups and Third Sector Organisations. She leads Cambridge Analytical Biotechnology, University of Cambridge. As a pioneering member in the Institute of Biotechnology she contributed to a unique Masters in Bioscience Enterprise (MBE).

Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products. We develop strategies and recommendations focused on product and portfolio planning, pricing and market access, and value communication.

We deliver strategic insights and actionable recommendations that help our clients tackle complex challenges and drive better decision-making. As a private firm, we work with companies large and small, helping clients confidently navigate the commercial landscape and ultimately deliver innovations that enhance the health of individuals and communities.

Our primary clients are pharmaceutical and biotech companies. They range from global brands that operate in multiple markets to small companies with limited product portfolios. They come to us for strategic insights to guide commercial decision making, and to identify, capture, and communicate the value of their products.

Within our client companies, we work with cross-functional teams — mainly those in commercial and pricing and market access functions.

Cambridge University MPhil in Bioscience Enterprise (MBE)

The Cambridge University MPhil in Bioscience Enterprise (MBE) programme is an intensive taught science and business course intended for those who have an interest in enterprise and the ambition to found technology companies or take up leadership, executive or consultancy roles in the life sciences sector.

The educational aims of the MBE are to:

  • enhance understanding of life sciences and related technological developments;

  • foster research and analytical skills and methodologies;

  • develop written and verbal communication skills;

  • provide knowledge of the ethical, legal and regulatory issues associated with bringing scientific advances to market; and

  • develop applied business skills, including those that enable students to:

  • identify potential business opportunities arising from research in life sciences and related areas;

  • exploit entrepreneurial opportunities; and

  • undertake senior executive roles within biotechnology companies and other commercial entities.

MBE students have the opportunity to learn from leading scientists, entrepreneurs and academics at the University of Cambridge, and from professionals within the Cambridge Cluster and wider industry.

 Contact us